| TaxTec, Proxymity and Label Launch End-to-End MiKaDiv Solution for Withholding Tax Compliance |
Globe Newswire |
04/13 |
02:53 |
| Baker Hughes Announces Sale of Waygate Technologies to Hexagon |
Globe Newswire |
04/13 |
02:00 |
| Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer |
Globe Newswire |
04/13 |
02:00 |
| SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT) |
Globe Newswire |
04/13 |
02:00 |
| CORRECTION - Israel Tech Week Moves Forward in Miami Amid Ongoing War in Israel |
Globe Newswire |
04/13 |
01:03 |
| WISeSat and Swiss Space Command of the Swiss Armed Forces Complete Pilot Phase and Prepare Next-Generation WISeSat 6U Mission Planned for November 2026 |
Globe Newswire |
04/13 |
01:00 |
| Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria |
Globe Newswire |
04/13 |
01:00 |
| Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE) |
Globe Newswire |
04/13 |
01:00 |
| Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) |
Globe Newswire |
04/13 |
01:00 |
| Strong Technical Services (STS) Announces Acquisition of CinemaNext U.S., Expanding Nationwide Service and Manufacturing Footprint |
Globe Newswire |
04/13 |
00:00 |
| Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia |
Globe Newswire |
04/12 |
19:30 |
| Kornit Digital Acquires PrintFactory to Accelerate the Industry’s Transition to Digital, On-Demand Production |
Globe Newswire |
04/12 |
18:00 |
| Kornit Digital Brings Global Apparel Leaders Together to Accelerate the Move Towards On-Demand Production |
Globe Newswire |
04/12 |
18:00 |
| Kornit Digital Redefines Apparel Production for the On-Demand Era Unveiling Atlas MATRIX at Konnections 2026 |
Globe Newswire |
04/12 |
18:00 |
| UniX AI Claims First Real-Home Deployment of Mass-Produced Humanoid Robot Panther |
Globe Newswire |
04/11 |
21:23 |
| Trillion Dollar Robot Under Investigation: New 2026 Report Highlights Nvidia AI Expansion, Autonomous Trucking Breakthroughs, and Rapid Expansion of Robotics Infrastructure |
Globe Newswire |
04/11 |
18:02 |
| AI's Second Wind Is Here — Weiss Ratings Plus Report Cites 303% Historical Average and 2026 Data Signals Pointing Beyond the First AI Cycle |
Globe Newswire |
04/11 |
17:45 |
| CSGORoll Casino Aims Best CSGO Gambling Site 2026 |
Globe Newswire |
04/11 |
16:24 |
| Safe Money Report Claims Evaluated: Health Bomb Analysis by Weiss Ratings Examines Healthcare Cost Pressures, Defensive Investment Strategies, and Economic Risk Factors for 2026 |
Globe Newswire |
04/11 |
15:54 |
| Gelatine Sculpt Unveiled: Does This Pink Gelatin Trick for Weight Loss Legit? Read Gelatine Sculpt Report! |
Globe Newswire |
04/11 |
15:09 |
| Bitcoin Casino No Deposit Bonus 2026: BitStarz Launches 50 Free Spins No Deposit Bonus with Instant Withdrawals |
Globe Newswire |
04/11 |
14:44 |
| BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer |
Globe Newswire |
04/11 |
07:00 |
| City Furniture and GARVEE Explore Omnichannel Retail Collaboration in North America |
Globe Newswire |
04/11 |
06:00 |
| NeuroSalt Under Investigation: What the 2026 Formulation Transparency Review Reveals About Botanical Ingredients, Dosage Disclosure, and Consumer Verification |
Globe Newswire |
04/10 |
23:29 |
| Alleron Expert Group Marks Six Years of 100% Client Retention, Announces Expanded Cloud Services Portfolio |
Globe Newswire |
04/10 |
23:26 |
